吡格列酮对非糖尿病代谢综合征患者的干预治疗

目的:观察吡格列酮对非糖尿病代谢综合征干预治疗的疗效。方法:选择非糖尿病代谢综合征患者84例,随机分为两组,A组(对照组)42例,予常规治疗;B组(干预组)42例,在常规治疗基础上加用吡格列酮15mg,每日1次口服,连服24周。监测治疗前、后空腹血糖(FPG)及餐后2h血糖(2HPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbAlc)、血脂、血压(BP)、胰岛素抵抗指数(HOMA-IR)、血清高敏C-反应蛋白(hsC-RP)等。结果:治疗24周后两组FPG、2HPG、FINS、HbAlc、BP、TG、hsC-RP及HOMA-IR均下降,HDL-C升高,B组下降明显,两组之间比较差异有统计学意义(P<0.05~P<0.01)。结论:对非糖尿病代谢综合征患者,吡格列酮可显著改善糖脂代谢,减轻IR和炎症状态,减少心血管疾病发生。

Intervention Study on Effect of Pioglitazone on Patients with Non-diabetic Metabolic Syndrome

Objective： To evaluate the intervention effect of pioglitazone on patients with non-diabetic metabolic syndrome（MS）. Methods. 84 non-diabetic MS patients were divided randomly into group A（n=42） ：conventional treatment only,and group B（n=42） ： pioglitazone 15mg po qd plus conventional treatment and continuous 24 weeks. Fasting plasma glucose（FPG）, postprandial glucose following meal 2 hours later（2HPG）, fasting insulin（FINS）, glycosylated hemoglobin（HbAlc ）, plasma lipid, HOMA-IR, SBP, DBP and hsC-RP were detected before and after medication separately. Results：After treatment, FPG. 2HPG, FINS. HbAlc. BP. TG. hsC-RP and HOMA-IR counts were decreased and HDL-C increased significantly in both groups. Which were changed more in group B than those in group A（P〈0. 05- P〈0.01）. Conclusion： In non-diabetic MS patients, pioglitazone can improve plasma glucose and lipids, less on insulin resistance and inflammatory state,reduction of the incidence of cardiovascular disease.